Nakamura Toshitaka
Department of Orthopedics, University of Occupational and Environmental Health, Japan.
Clin Calcium. 2012 Mar;22(3):309-14.
Teriparatide, a treatment formula of parathyroid hormone (PTH) , is a powerful anabolic agent on bone, improving its mass, geometry and microarchitecture. It can decrease the occurrence of fracture in the subjects with increased fracture risks. Teriparatide can provide good protection against fracture using as monotherapy, and possibly as combination with an antiresorptive agent such as zoledronate. Teriparatide should be considered in patients with osteoporosis who sustained the reduction of BMD or fracture on established bisphosphonates or SERMs. Treatment period of teriparatide is 1.5-2 years and consecutive use of antiresorptive agents is greatly recommended to secure long-term protection against fracture after teriparatide treatment.
特立帕肽是甲状旁腺激素（PTH）的一种治疗制剂，是一种强大的骨合成代谢药物，可改善骨量、骨几何形态和骨微结构。它能降低骨折风险增加的受试者发生骨折的几率。特立帕肽作为单一疗法使用时，可能与唑来膦酸等抗吸收药物联合使用时，均可为预防骨折提供良好的保护作用。对于在使用已确立的双膦酸盐或选择性雌激素受体调节剂（SERM）治疗后骨密度仍降低或发生骨折的骨质疏松症患者，应考虑使用特立帕肽。特立帕肽的治疗疗程为1.5至2年，强烈建议连续使用抗吸收药物，以确保在特立帕肽治疗后获得长期的骨折预防保护。
